<strong>Carocell Bio reveals positive new preclinical data from patient biopsies</strong>

san francisco biotech

Cheadle, UK – 10 January 2022 – Today, Carocell Bio, the anti-inflammation therapeutics company, announced that its lead anti-inflammatory peptide JEL3108 shows efficacy in human inflammatory disease tissue biopsies. The candidate peptide-based treatment provides an innovative approach to reduce pain and prevent scar formation after a burn and after surgery, through a novel, next-generation anti-inflammatory […]